BridgeBio is significantly improved its progress of an innovative treatment for cardiac amyloidosis, leveraging the investigational drug. Early trial data reveals potential benefits for individuals affected by the serious disease. This focus represents the company’s commitment to managing unmet medical needs in this heart field. Attruby: BridgeB